CD38 and Miyoshi myopathy: To determine a CD38-specific effect of ricolinostat, we analyzed the expression of B-cell maturation antigen (BCMA) [22, 23] and SLAM family member 7 (SLAMF7) [24], alternative targets in MM, after ricolinostat treatment.